In vitro antifungal susceptibility profile of Iranian Fusarium isolates: Emphasising on the potent inhibitory effect of efinaconazole compared to other drugs. Issue 3 (19th December 2022)
- Record Type:
- Journal Article
- Title:
- In vitro antifungal susceptibility profile of Iranian Fusarium isolates: Emphasising on the potent inhibitory effect of efinaconazole compared to other drugs. Issue 3 (19th December 2022)
- Main Title:
- In vitro antifungal susceptibility profile of Iranian Fusarium isolates: Emphasising on the potent inhibitory effect of efinaconazole compared to other drugs
- Authors:
- Nosratabadi, Mohsen
Faeli, Leila
Haghani, Iman
Mohammadi, Rasoul
Khodavaisy, Sadegh
Kachuei, Reza
Katiraee, Farzad
Aghili, Seyed Reza
Shokohi, Tahereh
Hedayati, Mohammad Taghi
Nazeri, Mehdi
Javan‐Nikkhah, Mohammad
Zarrinfar, Hossein
Javidnia, Javad
Najafzadeh, Mohammad‐Javad
Salimi, Maryam
M.S. Al Hatmi, Abdullah
Badali, Hamid
Abastabar, Mahdi - Abstract:
- Abstract: Background: Fusarium species are opportunistic human pathogens that remarkably cause fungal infections ranging from superficial to fatal invasive disseminated infections. Fusarium species are notoriously resistant to the majority of antifungal agents. Objectives: Therefore, detailed studies regarding in vitro susceptibility are required and may lead to a better prognosis of severe infections. Methods: We evaluated 25 antifungal drugs in vitro against 282 clinical and environmental Fusarium isolates. Results: Fusarium species demonstrated high MICs/MECs values to the most commonly used antifungal drugs in clinical practice. The geometric mean (GM) MICs for luliconazole (0.004 μg/ml) and lanoconazole (0.012 μg/ml) were the lowest, followed by efinaconazole (0.98 μg/ml) and amphotericin B (1.04 μg/ml). Conclusions: Efinaconazole, a novel triazole, may be a promising candidate for the treatment of superficial Fusarium infections. Furthermore, the development of systemic formulations of these drugs as well as further in vitro and in vivo investigations could aid in the treatment of systemic fusariosis.
- Is Part Of:
- Mycoses. Volume 66:Issue 3(2023)
- Journal:
- Mycoses
- Issue:
- Volume 66:Issue 3(2023)
- Issue Display:
- Volume 66, Issue 3 (2023)
- Year:
- 2023
- Volume:
- 66
- Issue:
- 3
- Issue Sort Value:
- 2023-0066-0003-0000
- Page Start:
- 258
- Page End:
- 275
- Publication Date:
- 2022-12-19
- Subjects:
- Fusarium -- Drug resistance -- Antifungal susceptibility -- Efinaconazole
Pathogenic fungi -- Periodicals
Medical mycology -- Periodicals
616.969 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1111/myc.13550 ↗
- Languages:
- English
- ISSNs:
- 0933-7407
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5995.753000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25715.xml